Table 5.

Summary of adverse events of special interest occurring the in the Japanese safety-evaluable subgroup

	Atezolizumab + nab-paclitaxel (n = 34)	Placebo + nab-paclitaxel(n = 30)
Patients with ≥ 1 event, n (%)	21 (61.8)	15 (50.0)
Rash	15 (44.1)	9 (30.0)
Hypothyroidism	6 (17.6)	1 (3.3)
Hepatitis (laboratory abnormalities)	5 (14.7)	8 (26.7)
Hepatitis (diagnosis)	2 (5.9)	0
Hyperthyroidism	2 (5.9)	0
Pneumonitis	1 (2.9)	0
Myositis	0	1 (3.3)
Grade 3–4 AEs, n (%)	0	2 (6.7)
Treatment-related grade 3–4 AEs	0	2 (6.7)